<DOC>
	<DOC>NCT00436839</DOC>
	<brief_summary>To compare overall survival after receiving mitoxantrone and prednisone or docetaxel and prednisone in subjects with hormone-refractory metastatic prostate cancer.</brief_summary>
	<brief_title>Taxotere Prostate Cancer New Indication Registration Trial in China</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Histologically or cytologically proven prostate adenocarcinoma Androgen independent prostate Cancer S/P orchiectomy and/or LHRH agonist Testosterone &lt; 50 ng/dl (ie 1.735 nmol/l) Documented progressive disease Patients should have achieved stable analgesia for 7 days Karnofsky Performance Status ≥ 70 No prior treatment with cytotoxic agent (except estramustine) Normal cardiac function must be confirmed by Left ventricular ejection fraction Adequate organ function: 1. Hematology: Neutrophils &gt; 1.5 x 10^9/L Hemoglobin &gt; 10 g/dl. Erythropoietin use is allowed, but red blood cell transfusion to upgrade the hemoglobin level is not allowed Platelets &gt; 100 x 10^9/L 2. Hepatic function: Total bilirubin &lt; the uppernormal limit of the institution. Alanine aminotransferase and Aspartate transaminase &lt; 1.5 times the uppernormal limit of the institution. 3. Renal function: Creatinine &lt; 1.5 times the upper normal limit (ie National Cancer Institution grade &lt; 1) No brain or leptomeningeal metastases Prior radiotherapy to &gt;25% of bone marrow (whole pelvic irradiation is not allowed) prior cytotoxic chemotherapy, except monotherapy with estramustine prior isotope therapy history of another cancer within the preceding five year symptomatic peripheral neuropathy grade ≥ 2 other serious illness or medical condition: 1. Congestive heart failure even if controlled. Previous history of myocardial infarction or angina pectoris within 1 year from study entry, uncontrolled hypertension or uncontrolled arrhythmias. 2. Active uncontrolled infection 3. Peptic ulcer, unstable diabetes mellitus or other contraindications for the use of corticosteroids. 4. Autoimmune disease (lupus, sclerodermia, rheumatoid polyarthritis) treatment with any other anticancer therapy treatment with bisphosphonates The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>